Surgical robotics innovator, SS Innovations International, Inc. (OTC: SSII) has successfully performed 500 surgeries using its flagship SSi Mantra Surgical Robotic System. The 500th surgery…
November 27, 2023
Lexaria Bioscience (Nasdaq: LEXX) has demonstrated that its DehydraTECH technology improves the performance of GLP-1 drug, semaglutide, in a human pilot study. DehydraTECH-powered semaglutide achieved…
November 21, 2023
FDA Says Alzamend Neuro Major Depressive Disorder Study May Proceed
Alzamend Neuro, Inc. (Nasdaq: ALZN) has received a “Study May Proceed” letter from the FDA for the initiation of study AL001-MDD01, a Phase 2a clinical…
November 21, 2023
BrainStorm Cell Therapeutics Granted FDA In-Person Meeting to Discuss Phase 3 Trial for ALS Treatment
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) will meet with the FDA to discuss the regulatory path forward for NurOwn® in amyotrophic lateral sclerosis (ALS) on…
November 20, 2023
MIRA Pharmaceuticals Enters Transformative Collaboration to Commercialize Ketamine Analog for Depression
Pharmaceutical company, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) has entered an exclusive licensing agreement with MIRALOGX, giving it the exclusive rights to develop and commercialize Ketamir-2…
MediciNova, Inc. (Nasdaq: MNOV) has presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the…
BioVie Inc. (NASDAQ: BIVI) has announced announced positive clinical safety data from the Company’s Phase 2b open-label study evaluating the efficacy and safety of BIV201…
November 16, 2023
Neuronetics Technology Advancements Enhance Depression Treatment
Medical technology company, Neuronetics, Inc. (NASDAQ: STIM), announced significant updates to its NeuroStar software and TrakStar® Patient Data Management System, a proprietary, HIPAA-compliant, patient management…
November 15, 2023
SciSparc Announces Major Breakthrough with Alzheimer’s Treatment
SciSparc Ltd (Nasdaq: SPRC) has announced positive topline results from its investigator-initiated Phase IIa trial evaluating its proprietary SCI-110 treatment for Alzheimer’s agitation. The trial…
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) has received FDA Fast Track Designation for CM-101 for the treatment of primary sclerosing cholangitis (PSC). PSC is a progressive,…
November 14, 2023
Esperion Presents Inflammation as Predictor of Cardiovascular Risk
Esperion Therapeutics (NASDAQ: ESPR) has presented results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results…
November 14, 2023
HeartSciences Technology Selected for Heart Screening of Irish Garda National Police Officers
Medical technology company, HeartSciences (Nasdaq: HSCS), has announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd to be used in its heart screening…